BR0315666A - Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos - Google Patents

Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos

Info

Publication number
BR0315666A
BR0315666A BR0315666-4A BR0315666A BR0315666A BR 0315666 A BR0315666 A BR 0315666A BR 0315666 A BR0315666 A BR 0315666A BR 0315666 A BR0315666 A BR 0315666A
Authority
BR
Brazil
Prior art keywords
type
antibodies
same
dna
proteins
Prior art date
Application number
BR0315666-4A
Other languages
English (en)
Other versions
BRPI0315666B1 (pt
BRPI0315666B8 (pt
Inventor
Matthew Scanlan
Gerd Ritter
Lloyd Old
Achim Jungbluth
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of BR0315666A publication Critical patent/BR0315666A/pt
Publication of BRPI0315666B1 publication Critical patent/BRPI0315666B1/pt
Publication of BRPI0315666B8 publication Critical patent/BRPI0315666B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

"DNA DE A34 E A33 DO TIPO 3, PROTEìNAS, SEUS ANTICORPOS E MéTODOS DE TRATAMENTO USANDO OS MESMOS". Moléculas de polinucleotídeo e moléculas de polipeptídeo A34 e A33 do tipo 3 são descritas, bem como anticorpos para as moléculas de polipeptídeo A34 e A33 do tipo 3. São também descritos métodos de detecção de cânceres expressando esses polipeptídeos e métodos e kits para diagnóstico dos ditos cânceres e métodos de inibição dos efeitos de um câncer em um paciente.
BRPI0315666A 2002-10-23 2003-10-23 dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos BRPI0315666B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42028502P 2002-10-23 2002-10-23
US60/420,285 2002-10-23
PCT/US2003/033707 WO2004037999A2 (en) 2002-10-23 2003-10-23 A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same

Publications (3)

Publication Number Publication Date
BR0315666A true BR0315666A (pt) 2005-08-30
BRPI0315666B1 BRPI0315666B1 (pt) 2019-04-30
BRPI0315666B8 BRPI0315666B8 (pt) 2021-05-25

Family

ID=32176548

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0315666A BRPI0315666B8 (pt) 2002-10-23 2003-10-23 dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos

Country Status (6)

Country Link
US (3) US7521543B2 (pt)
EP (1) EP1565482B1 (pt)
JP (1) JP2006512910A (pt)
AU (1) AU2003284891A1 (pt)
BR (1) BRPI0315666B8 (pt)
WO (1) WO2004037999A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP1888640B1 (en) 2005-05-18 2012-03-14 Ablynx N.V. Improved nanobodies against tumor necrosis factor-alpha
PL3415535T3 (pl) 2005-05-20 2021-06-14 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
WO2008074840A2 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
PT2190469E (pt) * 2007-09-04 2015-06-25 Compugen Ltd Polipéptidos e polinucleótidos, e utilizações dos mesmos como um alvo de fármacos para produzir fármacos e agentes biológicos
AU2013204943A1 (en) * 2007-09-04 2013-05-16 Compugen Ltd. Polypeptides and polynucleotides related to fxyd3, and uses thereof as a drug target for producing drugs and biologics
PL2769729T3 (pl) 2007-09-04 2019-09-30 Compugen Ltd. Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
EP2205249B1 (en) 2007-09-28 2018-11-07 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2009068630A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2009124931A2 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US8748581B2 (en) 2009-04-10 2014-06-10 Ablynx N.V. Anti-IL-6R polypeptides and pharmaceutical compositions thereof
SG176095A1 (en) 2009-06-05 2011-12-29 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
WO2011040978A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP2552947A4 (en) 2010-03-26 2013-11-13 Dartmouth College VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING ACTIVE SUBSTANCES AND USE THEREOF
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
EP2638068B1 (en) 2010-11-08 2018-12-26 Novartis AG Cxcr2 binding polypeptides
US8197471B1 (en) 2011-02-14 2012-06-12 Samuel Harry Tersigni Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
BR112014018481A2 (pt) 2012-02-01 2017-07-04 Compugen Ltd anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
AU2015357463B2 (en) * 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
CA2975078A1 (en) 2015-01-27 2016-08-04 Lava Therapeutics B.V. Single domain antibodies targeting cd1d
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
RU2018122255A (ru) 2015-11-27 2019-12-19 Аблинкс Нв Полипептиды, ингибирующие cd40l
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CA3020848A1 (en) 2016-04-15 2017-10-19 Janssen Pharmaceuticals, Inc. Anti-human vista antibodies and use thereof
EP3512880A1 (en) 2016-09-15 2019-07-24 Ablynx NV Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
CA3043515A1 (en) 2016-11-16 2018-05-24 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
CA3064469A1 (en) 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
MX2019014397A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Polipeptidos que enlazan adamts5, mmp13 y agrecano.
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
MX2019014400A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Inmunoglobulinas que se unen a adamts.
JP2021512947A (ja) 2018-02-06 2021-05-20 アブリンクス・エヌ・フェー Ｔｔｐの初回エピソードを免疫グロブリン単一可変ドメインで処置する方法
WO2020185069A1 (en) 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
WO2020245663A1 (en) 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
EP4214235A1 (en) 2020-09-16 2023-07-26 LinXis B.V. Internalizing binding molecules
EP4019548A1 (en) 2020-12-23 2022-06-29 Vrije Universiteit Brussel Anti lag3 vhhs and their use
CN115433733A (zh) 2021-06-04 2022-12-06 生物岛实验室 环状RNA Circ-ACE2翻译的多肽及其应用
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
CN114369162B (zh) 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708157A (en) * 1996-07-26 1998-01-13 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6312921B1 (en) 1996-07-26 2001-11-06 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1999060020A1 (en) 1998-05-18 1999-11-25 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
EP1432804A2 (en) * 2001-08-31 2004-06-30 Diadexus, Inc. Compositions and methods relating to ovary specific genes and proteins
WO2003042661A2 (en) * 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Also Published As

Publication number Publication date
AU2003284891A1 (en) 2004-05-13
WO2004037999A3 (en) 2005-06-30
EP1565482B1 (en) 2014-04-30
US20120039892A1 (en) 2012-02-16
US7521543B2 (en) 2009-04-21
EP1565482A4 (en) 2006-06-07
WO2004037999A2 (en) 2004-05-06
BRPI0315666B1 (pt) 2019-04-30
US20060292154A1 (en) 2006-12-28
US20090263394A1 (en) 2009-10-22
BRPI0315666B8 (pt) 2021-05-25
AU2003284891A8 (en) 2004-05-13
EP1565482A2 (en) 2005-08-24
JP2006512910A (ja) 2006-04-20
US8440807B2 (en) 2013-05-14

Similar Documents

Publication Publication Date Title
BR0315666A (pt) Dna de a34 e a33 do tipo 3, proteìnas, seus anticorpos e métodos de tratamento usando os mesmos
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
ATE416190T1 (de) Polypeptide mit bindungsaffinität für her2
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
AR026946A1 (es) Osteoprotegerina/receptores de factores de necrosis de tumores
CY1105212T1 (el) Αντισωματα αντι-april και κυτταρα υβριδωματος
ATE421537T1 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
ES2182297T3 (es) Deteccion y modulacion de lo inhibidores de las proteinas de la apoptosis (iaps) y de los polipeptidos anti-apoptoticos afines (naip) para la diagnosis y tratamiento de enfermedades proliferativas.
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
NO20062916L (no) Overflatelokaliserte campylobacter jejuni-polypeptider
DK1590467T3 (da) Anvendelse af regulatoriske sekvenser til specifik, transient ekspression i neuronalt bestemte celler
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
DE602005025231D1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
DK1082423T3 (da) Cyclin E2-gener og -proteiner
WO2003105773A3 (en) MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
SE0301987D0 (sv) New polypeptide

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: LUDWIG INSTITUTE FOR CANCER RESEARCH (US)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF